Cytograft maintains a focused product portfolio targeted at cell-based solutions to cardiovascular disease. The company's lead product has shown promising results in phase I/II clinical trials as reported in the Lancet.
Our follow-on products include the LifeGuard™ patch and the LifeJacket™ stent-graft. These products take advantage of Cytograft's expertise in Tissue Engineering by Self-Assembly (TESA) and biological based treatments. These follow-on technologies range from discovery stage to advanced pre-clinical research to support FIM (first in man).
The company is also developing a line of surgical devices to support percutaneous bypass and other minimally invasive surgical approaches.
Gant Chart - Development Stage